Results 151 to 160 of about 356,274 (192)

Phase II trial of the PARP inhibitor, niraparib, in BRCA1-Associated Protein 1 (BAP1) and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.

Journal of Clinical Oncology, 2021
TPS354 Background: BRCA1-Associated Protein 1 (BAP1) is a critical regulator of the cell cycle, cellular differentiation, cell death, and DNA damage response. It also acts as a tumor suppressor.
T. George, D. DeRemer, J. Lee, S. Staal, M. Markham, Dennie V. Jones, P. Hosein, K. Daily, J. Chatzkel, B. Ramnaraign, J. Close, M. Murphy, C. Allegra, S. Rogers, Azka Ali, R. Hromas   +15 more
semanticscholar   +1 more source

Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma.

Journal of Clinical Oncology, 2020
TPS591 Background: BRCA1-Associated Protein 1 (BAP1) is a critical regulator of the cell cycle, cellular differentiation, cell death, and DNA damage response. It also acts as a tumor suppressor.
T. George, D. DeRemer, Hiral D. Parekh, J. Lee, M. Markham, K. Daily, F. Kaye, S. Staal, Dennie V. Jones, B. Stechmiller, C. Allegra, R. Hromas   +11 more
semanticscholar   +1 more source

PREVALENCE OF MISMATCH REPAIR GENE MUTATIONS IN UVEAL MELANOMA.

Retina, 2020
PURPOSE Uveal melanomas are associated with characteristic genetic changes. Germline mutations in mismatch repair (MMR) genes and microsatellite instability have been implicated in the development of numerous malignant neoplasms such as colon and ovarian
C. Toomey, Nicholas J. Protopsaltis, Samantha Phou, M. Bakhoum, J. Thorson, L. Ediriwickrema, Bobby S. Korn, D. Kikkawa, M. Goldbaum, Jonathan H. Lin   +9 more
semanticscholar   +1 more source

Efficacy of combination immunotherapy in patients with generalized uveal melanoma: real clinical practice

Meditsinskiy sovet = Medical Council
Introduction. Uveal melanoma is a rare malignant neoplasm that develops from melanocytes of the choroid of the eyeball. It occupies a leading position in the structure of intraocular malignant neoplasms.Aim.
A. Sultanbaev, I. Tuzankina, A. Nasretdinov, N. Sultanbaeva, K. Menshikov, S. Musin, V. M. Zabelin, R. Ayupov, V. Askarov, R. Rakhimov, A. Izmailov, D. Kudlay   +11 more
semanticscholar   +1 more source

Uveal iridophoroma in a betta fish (Betta splendens).

Journal of Comparative Pathology
Chromatophoromas are neoplasms arising from pigment cells in vertebrates. Iridophoromas are a type of chromatophoroma that are reported in several teleost species. There are multiple case reports of this diagnosis in betta fish (Betta splendens), but all
Lisa Crevoiserat, Nina Katzenstein, E. LaDouceur   +2 more
semanticscholar   +1 more source

Abstract A07: Activating mutations in uveal melanoma convey sensitivity to g-alpha q inhibition

Cancer Research, 2020
Uveal melanoma (UVM) is the most common intraocular malignancy, which represents about 5% of all melanoma cases per year in the United States. Half of all patients eventually develop metastatic disease, resulting in an average survival rate of six ...
Tyler D. Hitchman, E. Ceraudo, Amanda R. Moore, A. Shoushtari, J. Francis, Y. Guan, Juliet Chen, Matthew T. Chang, B. Taylor, T. Sakmar, T. Huber, Ping Chi, Yu Chen   +12 more
semanticscholar   +1 more source

Sonographic signs of abdominal neoplasms in feline uveitis

International Journal of Veterinary Medicine
Feline uveitis is a common inflammatory disease of the vascular membrane of the eye. Damage to the uveal tract can be caused by a variety of causes, including systemic diseases, autoimmune processes, viral and bacterial infections, parasitic diseases ...
D. A. Vilmis
semanticscholar   +1 more source

Rate of second malignant neoplasm in a cohort of early stage uveal melanoma followed at Instituto Oncológico Henry Moore (IOHM) in the last 15 years.

Journal of Clinical Oncology, 2016
9587Background: Uveal melanoma (UM) is a rare neoplasm with a 3.3% rate of second malignant neoplasm (SMN) according to the Collaborative Ocular Melanoma Study (COMS) (Diener-West m et al.
Gaston Martin Reinas, Ernesto Gil Deza, Eduardo L. Morgenfeld, Flavio Tognelli, Marcelo Muino, Edgardo G. J. Rivarola, Felipe G. Gercovich   +6 more
openaire   +1 more source

Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347).

Journal of Clinical Oncology, 2020
e22061 Background: BRCA-associated protein-1 (BAP1) is a ubiquitin ligase associated with regulating cell cycle, cell proliferation, DNA damage pathway, and cell death.
Azka Ali, D. DeRemer, J. Lee, Hiral D. Parekh, S. Staal, M. Markham, K. Daily, B. Stechmiller, Dennie V. Jones, J. Close, M. Murphy, F. Kaye, C. Allegra, R. Hromas, T. George   +14 more
semanticscholar   +1 more source

Assessment of the survival rate of patients with malignant neoplasms of the choroid in the Orenburg region

Russian Ophthalmological Journal
The purpose of the work is to analyze the impact of various factors on the survival of patients with malignant neoplasms of the choroid. Materials and methods. A retrospective analysis of the databases of the V.I. Voynov Orenburg State Clinical
A. E. Aprelev, D. N. Begun, I. Zakirova, S. A. Shmitkova   +3 more
semanticscholar   +1 more source